Swedish Orphan Biovitrum AB (publ) (B6E.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
As of 08:01AM CEST. Market open.
| Previous Close | 23.86 |
| Open | 23.98 |
| Bid | 23.98 x 76000 |
| Ask | 24.40 x 74000 |
| Day's Range | 23.98 - 23.98 |
| 52 Week Range | 16.13 - 26.46 |
| Volume | |
| Avg. Volume | 5 |
| Market Cap | 8.287B |
| Beta (5Y Monthly) | 0.25 |
| PE Ratio (TTM) | 44.41 |
| EPS (TTM) | 0.54 |
| Earnings Date | Jul 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireSobi has completed SEK 3 billion senior bond issue
Swedish Orphan Biovitrum AB (publ) (Sobi®) has successfully completed the inaugural issue of senior unsecured bonds of SEK 3 billion under its newly established MTN programme.
PR NewswireSobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
PR NewswireSobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
© 2024 Yahoo. All rights reserved.